
LIST OF FIGURES

Figure No.	Title	Page No.
2.1	Key mechanisms of drug resistance in breast cancer	24
2.2	Classification of NLCs	31
3.1	Graph of Linearity of Paclitaxel	71
3.2	Overlay of Linearity chromatograms of Paclitaxel	71
3.3	Chromatograms for Specificity [A] Paclitaxel in NLCs [B] Paclitaxel in Microemulsion [C] Placebo NLCs [D] Placebo Microemulsion	72
3.4	Graph of Linearity of Cyclophosphamide	76
3.5	Overlay of Linearity chromatograms of Cyclophosphamide	
3.6	Chromatograms for Specificity [A] Cyclophosphamide in NLCs [B] Cyclophosphamide in Microemulsion [C] Placebo NLCs [D] Placebo Microemulsion	77
4.1	FTIR Spectrum of Paclitaxel	87
4.2	FTIR Spectrum of Cyclophosphamide	88
4.3	UV scan of Paclitaxel API	88
4.4	UV scan of Cyclophosphamide API	89
4.5	Solubility of Paclitaxel in different solid lipids	89
4.6	Solubility of Paclitaxel in different liquid lipids/ oils	90
4.7	FTIR Spectra of Paclitaxel – Excipient Compatibility studies	92
4.8	FTIR Spectra of Cyclophosphamide – Excipient Compatibility studies	93
4.9	Overlay of Chromatograms for Drug-Drug and Drug-Excipient compatibility studies	94
5.1	Manufacturing process of Paclitaxel and Cyclophosphamide loaded NLCs	104
5.2	Ishikawa diagram of Paclitaxel and Cyclophosphamide loaded NLCs	109
5.3	Freeze drying microscopy of Optimized NLCs	136
5.4	Screenshot of Representative SMARTTM programme	137
5.5	Graph of Particle size distribution of NLCs	143
5.6	Graph of Zeta Potential of NLCs	143
5.7	FTIR Spectra of [A] Paclitaxel pure drug [B] Cyclophosphamide pure drug [C] Paclitaxel and Cyclophosphamide loaded NLCs [D] Placebo NLCs	145

Figure No.	Title	Page No.
5.8	DSC Thermograms [A] Pure Paclitaxel [B] Pure Cyclophosphamide [C] Paclitaxel & Cyclophosphamide loaded NLCs [D] Placebo NLCs	147
5.9	XRD graph [A] Pure Paclitaxel [B] Pure Cyclophosphamide [C] Paclitaxel and Cyclophosphamide loaded NLCs [D] Placebo NLCs	150
5.10	TEM Images of PAC-CYC loaded NLCs [A]: Before lyophilization [B & C]: After SMARTTM lyophilization	151
5.11	Graph of % cumulative drug release vs. time in hours for Paclitaxel & Cyclophosphamide loaded NLCs, Pure Paclitaxel, and Pure Cyclophosphamide	151
5.12	Sterility testing [A] Negative Control (Water for Injection) [B] Positive Control for Soybean casein digest medium (SCDM) [C] Test NLCs in SCDM [D] Positive control for Fluid Thioglycolate Medium (FTM) [E] Test NLCs in FTM	153
6.1	Manufacturing process of Paclitaxel and Cyclophosphamide Microemulsion	180
6.2	Ishikawa diagram of Paclitaxel and Cyclophosphamide Microemulsion	185
6.3	Pseudo ternary diagram	199
6.4	Graph of Zeta Potential of microemulsion	205
6.5	Graph of Particle size distribution of Microemulsion	206
6.6	TEM Image of Optimized Microemulsion	207
6.7	Graph of % cumulative drug release vs. time in hours for Paclitaxel & Cyclophosphamide loaded microemulsion, INTAXEL and CYTOXAN	208
6.8	Sterility testing [A] Negative Control (Water for Injection) [B] Positive Control for Soybean casein digest medium (SCDM) [C] Test Microemulsion in SCDM [D] Positive control for Fluid Thioglycolate Medium (FTM) [E] Test Microemulsion in FTM	209
7.1	Response Additivity graph of Paclitaxel and Cyclophosphamide alone versus Paclitaxel and Cyclophosphamide combination (1: 8.75)	231
7.2	Results of In-vitro Cytotoxicity study	235
7.3	Cellular Uptake and Apoptosis study by Fluorescence Microscopy of [A] Pure Paclitaxel and [B] Pure Cyclophosphamide	238
7.4	Cellular Uptake Assay and Apoptosis by Fluorescence Microscopy of [A] PAC-CYC loaded NLCs and [B] PAC-CYC loaded microemulsion	238
7.5	Cell cycle distribution in MCF-7 cells using Flow cytometry	241

Figure No.	Title	Page No.
7.6	Observed Tumor volume for Disease control vs. Treatment groups	244
7.7	Images of tumor for disease control, INTAXEL [®] , ENDOXAN [™] , PAC-CYC NLCs and PAC-CYC Microemulsion	245
7.8	Histological micrographs of Normal control group showing normal adipose tissue, epithelial cells, normal ducts and epithelial cells	246
7.9	Histological micrographs of Disease control group	247
7.10	Histological micrographs of group treated with INTAXEL	249
7.11	Histological micrographs of group treated with ENDOXAN	249
7.12	Histological micrographs of group treated with PAC-CYC NLCs	251
7.13	Histological micrographs of group treated with PAC-CYC Microemulsion	252